TXG: Institutional Interest And New Assay Expected To Influence Future Performance

Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.

Analyst Commentary

Analyst perspectives on 10x Genomics highlight both opportunities for growth and caution around near-term challenges. Recent coverage and investment activity have contributed to a nuanced view of the company’s outlook.

Bullish Takeaways

• Several analysts see 10x Genomics as having a leading position in single cell technology, supported by the largest installed base and technological leadership among competitors.
• The company is viewed as a favored name within the tools sector. This reflects optimism about management's ability to reaccelerate growth.
• Bullish analysts recently raised their price targets and pointed to signs of improving financial performance, including revenue growth and profitability trends.
• Recent substantial share purchases by prominent investors suggest increased confidence in the company's long-term prospects and current valuation.

Bearish Takeaways

• Some analysts maintain a more cautious stance and recommend that investors wait for improved visibility on the macro environment before increasing positions.
• Despite technological strengths, short-term headwinds related to market conditions and execution risk are areas of focus for more bearish analysts.
• Valuation remains a point of debate, with some viewing shares as fairly valued given lingering uncertainties.

What's in the News

• Cathie Wood's ARK Investment purchased 222,000 shares of 10x Genomics, highlighting increased institutional confidence (Periodical).
• 10x Genomics provided revenue guidance for Q4 2025, expecting $154 million to $158 million in revenue. This guidance reflects a 6% decline year-over-year and 5% sequential growth at the midpoint (Key Developments).
• The company launched the next generation of its high-performance Flex assay, which enables automation-compatible plate-based multiplexing with the ability to profile up to 384 samples and 100 million cells per week (Key Developments).
• 10x Genomics and Anthropic announced a collaboration to integrate 10x's analysis tools with the Claude AI platform. This integration will allow researchers to analyze single cell and spatial datasets through conversational interfaces (Key Developments).
• CLISEQ Ltd. and 10x Genomics began a global clinical research study, PERIBLOOD, to evaluate the use of single cell RNA sequencing of peripheral blood as an alternative to bone marrow aspiration for diagnosing hematologic disorders (Key Developments).

Valuation Changes

• The consensus analyst price target has increased slightly from $15.08 to $15.86 per share.
• The discount rate has risen modestly from 7.24% to 7.81%.
• The revenue growth projection has improved, moving from 2.22% to 2.70%.
• The net profit margin is up from 14.21% to 15.70%.
• The future P/E has declined marginally from 25.67x to 25.32x.